Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Cited by (7,499)

Items 1,301–1,400 of 7,499

1. The Susceptibility Genes in Diabetic Nephropathy
   Ling Wei, Ying Xiao, Li Li · 2018 · Kidney Diseases
2. Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
   Gabriel Helmlinger, Victor V. Sokolov, Kirill V. Peskov, K. Melissa Hallow, Yuri Kosinsky, Veronika Voronova, Lulu Chu, Tatiana A. Yakovleva, Ivan Azarov, Daniel Kaschek et al. · 2019 · CPT Pharmacometrics & Systems Pharmacology
3. Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020
   Susanne B. Nicholas, Kenn B. Daratha, Radica Z. Alicic, Cami R. Jones, Lindsey M. Kornowske, Joshua J. Neumiller, Samuel Fatoba, Sheldon Xiaodong Kong, Rakesh Singh, Keith C. Norris et al. · 2023 · Diabetes Obesity and Metabolism
4. Renin-angiotensin-aldosterone system: Fundamental aspects and clinical implications in renal and cardiovascular disorders
   Mark Anthony Perazella, John Francis Setaro · 2003 · Journal of Nuclear Cardiology
5. High Glucose Induces Podocyte Injury via Enhanced (Pro)renin Receptor-Wnt-β-Catenin-Snail Signaling Pathway
   Caixia Li, Helmy M. Siragy · 2014 · PLoS ONE
6. Timing of Arteriovenous Fistula Creation in Patients With CKD: A Decision Analysis
   Steven M. Shechter, M. Reza Skandari, Nadia Zalunardo · 2013 · American Journal of Kidney Diseases
7. Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes
   Piero Luigi Ruggenenti, Annalisa Perna, Maria G. Ganeva, Bogdan Ene‐Iordache, Giuseppe Remuzzi · 2006 · Journal of the American Society of Nephrology
8. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy
   Rajiv Agarwal, Chandan Saha, Meher Battiwala, Nina Vasavada, Timothy M. Curley, Shawn D. Chase, Nadine G. Sachs, Merfake H. Semret · 2005 · Kidney International
9. Disease modification and cardiovascular risk reduction: two sides of the same coin?
   Frances C. Hall, Nicola Dalbeth · 2005 · Rheumatology
10. Tissue Gene Expression of Renin-Angiotensin System in Human Type 2 Diabetic Nephropathy
    Tadashi Konoshita, Shigeyuki Wakahara, Shinichi Mizuno, Makoto Motomura, Chikako Aoyama, Yasukazu Makino, Yasuyuki Kawai, Norihiro Kato, Ichiro Koni, Isamu Miyamori et al. · 2006 · Diabetes Care
11. Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial
    José Ramón González‐Juanatey, Pilar Mazón Ramos, Federico Soria Arcos, Vivencio Barrios Alonso, Luis Rodrı́guez Padial, Vicente Bertoméu · 2003 · Revista Española de Cardiología
12. Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease
    William H. Herman, Shahnaz Shahinfar, George W. Carides, Erik J. Dasbach, William C. Gerth, Charles M. Alexander, J.R. Cook, William F. Keane, Barry Morton Brenner, For the RENAAL Investigators · 2003 · Diabetes Care
13. Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy
    Ren R Wenzel · 2005 · Drugs
14. Association between genetic polymorphism of the angiotensin-converting enzyme and diabetic nephropathy: a meta-analysis comprising 26,580 subjects
    Furu Wang, Qiaoqiao Fang, Ningle Yu · 2011 · Journal of the Renin-Angiotensin-Aldosterone System
15. African Americans, hypertension and the renin angiotensin system
    Sandra F. Williams · 2014 · World Journal of Cardiology
16. Evidence‐based guide to slowing the progression of early renal insufficiency
    David Wayne Johnson · 2004 · Internal Medicine Journal
17. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis
    Jing Yun Hou, Weiquan Xiong, Ling Cao, Xiangqiong Wen, Ailing Li · 2015 · Clinical Therapeutics
18. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials
    Finlay Aleck McAlister, for the Renin Angiotension System Modulator Meta-Analysis Investigators · 2011 · European Heart Journal
19. Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial
    Yongchun Ge, Honglang Xie, Shijun Li, Bo Jin, Jinhua Hou, Haitao Zhang, Mingjun Shi, Zhihong Liu · 2013 · Journal of Translational Medicine
20. Causes and Consequences of Chronic Kidney Disease: Implications for Managed Health Care
    Daniel E. Weiner · 2007 · Journal of Managed Care Pharmacy
21. Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials
    W.J. Elliott · 2006 · Yearbook of Cardiology
22. Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
    Lama Ghazi, Paul E. Drawz · 2017 · F1000Research
23. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus
    Enrico Agabiti Rosei, Damiano Rizzoni, María Lorenza Muiesan, Intissar Sleiman, Massimo Salvetti, Cristina Monteduro, Enzo Porteri · 2005 · Journal of Hypertension
24. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients – interaction with ACE insertion/deletion polymorphism
    Wing‐Yee So, R.C.W. Ma, Risa Ozaki et al. · 2006 · Kidney International
25. Review: Potential of renin inhibition in cardiovascular disease
    Alice V. Stanton · 2003 · Journal of the Renin-Angiotensin-Aldosterone System
26. A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
    Ty J. Gluckman, Bryan J. Baranowski, M. Dominique Ashen, Charles A. Henrikson, Marc W McAllister, Joel B. Braunstein, Roger Scott Blumenthal · 2004 · Archives of Internal Medicine
27. Parkinson’s progression markers initiative: a milestone-based strategy to monitor Parkinson’s disease progression
    Brumm, Michael C., Siderowf, Andrew, Simuni, Tanya, Burghardt, Elliot, Choi, Seung Ho, Caspell-Garcia, Chelsea, Chahine, Lana M., Mollenhauer, Brit, Foroud, Tatiana, Galasko, Douglas et al. · 2023 · Journal of Parkinson’s Disease
28. Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association
    Khan, Sadiya S., Breathett, Khadijah, Braun, Lynne T., Chow, Sheryl L., Gupta, Deepak K., Lekavich, Carolyn, Lloyd-Jones, Donald M., Ndumele, Chiadi E., Rodriguez, Carlos J., Allen, Larry A. et al. · 2025 · Circulation
29. Hydrogen sulfide improves endothelial dysfunction by inhibiting the vicious cycle of NLRP3 inflammasome and oxidative stress in spontaneously hypertensive rats
    Jiabao Li, Xu Teng, Sheng Jin, Jinghui Dong, Qi Guo, Danyang Tian, Yuming Wu · 2019 · Journal of Hypertension
30. Type 2 Diabetes
    Sandeep S. Vijan · 2019 · Annals of Internal Medicine
31. Cardiorenal benefits of finerenone: protecting kidney and heart
    José Ramón González‐Juanatey, José Luis Górriz, Alberto Ortíz, Alfonso Valle, María José Soler, Lorenzo Fácila · 2023 · Annals of Medicine
32. Chronic Kidney Disease Progression—A Challenge
    Silvio Maringhini, Carmine Zoccali · 2024 · Biomedicines
33. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension
    Hao Xue, Zhuang Lu, Wen Lu Tang, Lu Wei Pang, Gan Mi Wang, Gavin WK Wong, James M Wright · 2015 · Cochrane Database of Systematic Reviews
34. Factors influencing the development of end-stage renal disease
    Kunitoshi Iseki · 2005 · Clinical and Experimental Nephrology
35. Efficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-Analysis
    Paweena Susantitaphong, Kamal Sewaralthahab, Ethan M. Balk, Somchai Eiam‐Ong, Nicolaos E. Madias, Bertrand L. Jaber · 2013 · American Journal of Hypertension
36. Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial
    Shuei‐Liong Lin, Yung‐Ming Chen, Wen‐Chih Chiang · 2008 · American Journal of Kidney Diseases
37. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes
    Anupama Mohanram, Zhong-yan Zhang, S. Shahinfar, Paulette A. Lyle, Robert D. Toto · 2007 · Kidney International
38. Phosphorylation of Nephrin Triggers Ca2+ Signaling by Recruitment and Activation of Phospholipase C-γ1
    Yutaka Harita, Hidetake Kurihara, Hidetaka Kosako, Tohru Tezuka, Takashi Sekine, Takashi Igarashi, Ikuroh Ohsawa, Shigeo Ohta, Seisuke Hattori · 2009 · Journal of Biological Chemistry
39. Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy
    Shinji Kume, Munehiro Kitada, Keizo Kanasaki, Hiroshi Maegawa, Daisuke Koya · 2013 · Archives of Pharmacal Research
40. Principles of Screening for Chronic Kidney Disease
    Bernard G. Jaar, Rasha Khatib, Laura Plantinga, L. Ebony Boulware, Neil R. Powe · 2007 · Clinical Journal of the American Society of Nephrology
41. Potential role of active vitamin D in retarding the progression of chronic kidney disease
    J. Tian, Youhua Liu, Laura A. Williams, Dick de Zeeuw · 2006 · Nephrology Dialysis Transplantation
42. Diabetic cardiomyopathy: a clinical entity or a cluster of molecular heart changes?
    Maria Mizamtsidi, Stavroula Α. Paschou, Julia Grapsa, Andromachi Vryonidou · 2016 · European Journal of Clinical Investigation
43. Recommendations for the screening and management of patients with chronic kidney disease
    Jérôme Rossert, Jean‐Pierre Wauters · 2002 · Nephrology Dialysis Transplantation
44. The tissue renin–angiotensin system and intracellular signalling
    Ingrid Fleming, Karin Kohlstedt, Rudi Busse · 2005 · Current Opinion in Nephrology & Hypertension
45. The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
    Aslam Amod · 2012 · Journal of Endocrinology Metabolism and Diabetes of South Africa
46. Improved prognosis of diabetic nephropathy in type 1 diabetes
    Guðbjörg Andrésdóttir, Majken Linnemann Jensen, Bendix Carstensen, Hans‐Henrik Parving, Peter Hambak Hovind, Tine W. Hansen, Peter R Rossing · 2014 · Kidney International
47. Hypertension in chronic kidney disease—treatment standard 2023
    Panagiotis I. Georgianos, Rajiv Agarwal · 2023 · Nephrology Dialysis Transplantation
48. Rapid Progression of Diabetic Nephropathy Is Linked to Inflammation and Episodes of Acute Renal Failure
    Katherine J. Kelly, Jesus H. Dominguez · 2010 · American Journal of Nephrology
49. The Angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer
    Mitsuyoshi Okazaki, Sachio Fushida, Shinichi Harada, Tomoya Tsukada, Jun Kinoshita, Katsunobu Oyama, Hidehiro Tajima, Itasu Ninomiya, Takashi Fujimura, Tetsuo Ohta · 2014 · Cancer Letters
50. Gq signaling causes glomerular injury by activating TRPC6
    Liming Wang, Grant Jirka, Paul B. Rosenberg, Anne F. Buckley, Jose A. Gomez, Timothy A. Fields, Michelle P. Winn, Robert F. Spurney · 2015 · Journal of Clinical Investigation
51. A Comparison of Iothalamate-GFR and Serum Creatinine-Based Outcomes
    Julia Breyer Lewis, Tom Greene, Lawrence J. Appel, Gabriel N. Contreras, Janice G. Douglas, Jim Lash, Robert D. Toto, Fredrick Van Lente, Xuelei Wang, Jackson T. Wright · 2004 · Journal of the American Society of Nephrology
52. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli
    Zhong-Gao Xu, Tae‐Hyun Yoo, Dong‐Ryeol Ryu · 2005 · Kidney International
53. ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney
    Jan A Wysocki, David I. Ortiz-Melo, Natalie K Mattocks, Katherine H. Xu, Jessica Prescott, Karla Evora, Minghao Ye, Matthew A. Sparks, Syed K. Haque, DANIEL C. BATLLE et al. · 2014 · Physiological Reports
54. Recurrence of Secondary Glomerular Disease after Renal Transplantation
    Claudio E. Ponticelli, Gabriella Luisa Moroni, Richard J. Glassock · 2011 · Clinical Journal of the American Society of Nephrology
55. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria
    Giuseppe Mulè, Antonella Castiglia, Claudia Cusumano, Emilia Scaduto, Giulio Geraci, Dario C. Altieri, Epifanio Di Natale, Onofrio Cacciatore, Giovanni Cerasola, Santina Cottone · 2016 · Advances in experimental medicine and biology
56. Metformin: A Candidate Drug for Renal Diseases
    Raphaëlle Corremans, Benjamin A. Vervaet, Patrick C. D’Haese, Ellen Neven, Anja Verhulst · 2018 · International Journal of Molecular Sciences
57. Analysis of Factors Causing Hyperkalemia
    Kenmei Takaichi, Fumi Takemoto, Yoshifumi Ubara, Yasumichi Mori · 2007 · Internal Medicine
58. ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells
    Yuki Izawa, Masanori Yoshizumi, Yoshiko Fujita, Nermin Ali, Yasuhisa Kanematsu, Keisuke Ishizawa, Koichiro Tsuchiya, Toshiyuki Obata, Yousuke Ebina, Shuhei Tomita et al. · 2005 · Experimental Cell Research
59. Optimal dose of losartan for renoprotection in diabetic nephropathy
    Steen Andersen · 2002 · Nephrology Dialysis Transplantation
60. Impact of ACE Inhibitors and AII Receptor Blockers on Peritoneal Membrane Transport Characteristics in Long-Term Peritoneal Dialysis Patients
    Inna Kolesnyk, Friedo Wilhelm Dekker, Marlies Noordzij, Saskia le Cessie, Dirk Gijsbert Struijk, Raymond Theodorus Krediet · 2007 · Peritoneal Dialysis International
61. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases
    Bramlage, Peter, Lanzinger, Stefanie, van Mark, Gesine, Hess, Eva, Fahrner, Simon, Heyer, Christoph H. J., Friebe, Mathias, Seufert, Jochen, Danne, Thomas, Holl, Reinhard W. · 2019 · Cardiovascular Diabetology
62. Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)
    Lambers Heerspink, Hiddo J., Weldegiorgis, Misghina, Inker, Lesley A., Gansevoort, Ron, Parving, Hans-Henrik, Dwyer, Jamie P., Mondal, Hasi, Coresh, Josef, Greene, Tom, Levey, Andrew S. et al. · 2014 · American Journal of Kidney Diseases
63. Improving Care of Patients With Diabetes and CKD: A Pilot Study for a Cluster-Randomized Trial
    Laura Cortés–Sanabria, Carlos Enrique Cabrera-Pivaral, Alfonso Martin Cueto-Manzano, Enrique Rojas Campos, Graciela Barragán, Moisés Hernández-Anaya, Héctor R. Martínez–Ramírez · 2008 · American Journal of Kidney Diseases
64. Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes
    Sridevi Gutta, Nadja Grobe, Meenasri Kumbaji, Hassan Osman, Mohammad G. Saklayen, Gengxin Li, Khalid M. Elased · 2018 · American Journal of Physiology-Renal Physiology
65. Serum-Free Medium Enhances the Immunosuppressive and Antifibrotic Abilities of Mesenchymal Stem Cells Utilized in Experimental Renal Fibrosis
    Ken Yoshida, Ayumu Nakashima, Shigehiro Doi, Toshinori Ueno, Tomoe Okubo, Ki-ichiro Kawano, Masami Kanawa, Yukio Kato, Yukihito Higashi, Takao Masaki · 2018 · Stem Cells Translational Medicine
66. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations
    Giovanna Leoncini, Francesca Chiara Viazzi, Salvatore De Cosmo, Giuseppina Tiziana Russo, Paola Fioretto, Roberto Pontremoli · 2020 · Journal of Nephrology
67. Astragaloside II Ameliorated Podocyte Injury and Mitochondrial Dysfunction in Streptozotocin-Induced Diabetic Rats
    Jun Su, Chongting Gao, Ling Xie, Ying Fan, Yilan Shen, Qunwei Huang, Niansong Wang, Youhua Xu, Nizhi Yang, Dingkun Gui · 2021 · Frontiers in Pharmacology
68. Reporting of Estimated GFR in the Primary Care Clinic
    Christina M. Wyatt, Vinaya Konduri, John Eng, Rajeev Rohatgi · 2007 · American Journal of Kidney Diseases
69. Dietary protein restriction benefits patients with chronic kidney disease (Review Article)
    Sreedhar A. Mandayam, William E. Mitch · 2006 · Nephrology
70. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria
    Keith Tse, F K Li, S Tang · 2005 · Lupus
71. Interpreting Treatment Effects From Clinical Trials in the Context of Real-World Risk Information
    Ann M. O’Hare, John R. Hotchkiss, Manjula Kurella Tamura, Eric Berg Larson, Brenda R. Hemmelgarn, Adam Batten, Thy P. Do, Kenneth E. Covinsky · 2014 · JAMA Internal Medicine
72. Autophagy: Emerging Therapeutic Target for Diabetic Nephropathy
    Shinji Kume, Kosuke Yamahara, Mako Yasuda, Hiroshi Maegawa, Daisuke Koya · 2013 · Seminars in Nephrology
73. Plasma Prekallikrein
    Ayad A. Jaffa, Ramón Durazo-Arvizú, Deyi Zheng · 2003 · Diabetes
74. SEQUENTIAL ACTIVATION OF THE REACTIVE OXYGEN SPECIES/ANGIOTENSINOGEN/RENIN–ANGIOTENSIN SYSTEM AXIS IN RENAL INJURY OF TYPE 2 DIABETIC RATS
    Kayoko Miyata, Naro Ohashi, Yuki Suzaki, Akemi Katsurada, Hiroyuki Kobori · 2008 · Clinical and Experimental Pharmacology and Physiology
75. Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease
    Hala Yamout, Ivana Lazich, George L. Bakris · 2014 · Advances in Chronic Kidney Disease
76. The Prevalence of CKD in Rural Canadian Indigenous Peoples: Results From the First Nations Community Based Screening to Improve Kidney Health and Prevent Dialysis (FINISHED) Screen, Triage, and Treat Program
    Paul V. J. Komenda, Barry Lavallee, Thomas W. Ferguson, Navdeep Tangri, Caroline Chartrand, Lorraine McLeod, Audrey Gordon, Allison B. Dart, Claudio Rigatto · 2016 · American Journal of Kidney Diseases
77. Glomerular Endothelial Cell Stress and Cross-Talk With Podocytes in Early Diabetic Kidney Disease
    Ilse Sofia Daehn · 2018 · Frontiers in Medicine
78. Anti-fibrotic treatments: A review of clinical evidence
    Marco Allinovi, Letizia De Chiara, Maria Lucia Angelotti, Francesca Becherucci, Paola Romagnani · 2018 · Matrix Biology
79. Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease
    Brian D. Radbill, Barbara T. Murphy, Derek LeRoith · 2008 · Mayo Clinic Proceedings
80. Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program
    Wendy Weinstock Brown, Allan Collins, Shu‐Cheng Chen, Karren King, Donald A. Molony, Monica Ryan Gannon, Gigi Politoski, William F. Keane · 2003 · Kidney International
81. Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome
    William H. Bestermann, Mark C. Houston, Ralph G. Hawkins, Jan Basile, Brent M. Egan, Dan Lackland, Carlos Maria Ferrario, Michael A. Moore, James W. Reed, Philip Rogers et al. · 2005 · The American Journal of the Medical Sciences
82. Prevention of the development and progression of renal disease.
    T. Hostetter · 2003 · Journal of the American Society of Nephrology
83. AT1 and AT2 receptor in the kidney: role in health and disease
    Helmy M. Siragy · 2004 · Seminars in Nephrology
84. Obesity, Hypertension, and Insulin Resistance
    Zachary T. Bloomgarden · 2002 · Diabetes Care
85. The importance of diabetic nephropathy in current nephrological practice
    Francesco Locatelli · 2003 · Nephrology Dialysis Transplantation
86. Concomitance of Diabetic Retinopathy and Proteinuria Accelerates the Rate of Decline of Kidney Function in Type 2 Diabetic Patients
    Roberto Trevisan, Monica Vedovato, Cinzia Mazzon · 2002 · Diabetes Care
87. Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease
    Ron T. van Domburg, Sanne Elisabeth Hoeks, Gijs M. J. M. Welten, Michel Chonchol, Abdou Elhendy, Don Poldermans · 2008 · Journal of the American Society of Nephrology
88. Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence
    Norman M. Kaplan · 2001 · Annals of Internal Medicine
89. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004
    Philip Kam‐Tao Li, Jan J. Weening, John Dirks, Sing Leung Lui, Cheuk‐Chun Szeto, Sydney C.W. Tang, Robert C. Atkins, William E. Mitch, Kai Ming Chow, Giuseppe D’Amico et al. · 2005 · Kidney International
90. Prevention of Cardiovascular Disease in Type 1 Diabetes
    Camila Manrique‐Acevedo, Irl B. Hirsch, Robert H. Eckel · 2024 · New England Journal of Medicine
91. Diabetes UK and South Asian Health Foundation recommendations on diabetes research priorities for British South Asians
    Kamlesh K. Khunti, Sudhesh Kumar, Jo Brodie · 2009
92. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension
    Sverre Erik Kjeldsen · 2004 · Heart Drug
93. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS)
    for the Japan Diabetes Complications Study Group, Shigehiro Katayama, Tatsumi Moriya, Shiro Tanaka, Shiro Tanaka, Yoshitada Yajima, Hirohito Sone, Satoshi Iimuro, Yasuo Ohashi, Y Akanuma et al. · 2011 · Diabetologia
94. Comparison of Associations of Urine Protein-Creatinine Ratio Versus Albumin-Creatinine Ratio With Complications of CKD: A Cross-sectional Analysis
    Herrick Fisher, Chi‐yuan Hsu, Eric Vittinghoff, Feng Lin, Nisha Bansal · 2013 · American Journal of Kidney Diseases
95. Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors
    Laurie Howes · 2008 · Vascular Health and Risk Management
96. Visceral and Subcutaneous Adiposity and Brachial Artery Vasodilator Function
    Nisha I. Parikh, Michelle J. Keyes, Martin G. Larson, Karla M. Pou, Naomi M. Hamburg, Joseph A. Vita, Christopher J. O’Donnell, Ramachandran Srini Vasan, Gary F. Mitchell, Udo Hoffmann et al. · 2009 · Obesity
97. Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?
    Michel Burnier · 2009 · Journal of International Medical Research
98. Circadian CLOCK Mediates Activation of Transforming Growth Factor-β Signaling and Renal Fibrosis through Cyclooxygenase 2
    Wei-Dar Chen, Jih‐Kai Yeh, Meng‐Ting Peng, Shian‐Sen Shie, Shuei‐Liong Lin, Chia‐Hung Yang, Tien‐Hsing Chen, Kuo‐Chun Hung, Chun‐Chieh Wang, Ching‐Lin Hsieh et al. · 2015 · American Journal Of Pathology
99. Developing Treatments for Chronic Kidney Disease in the 21st Century
    Matthew Douglas Breyer, Katalin Suszták · 2016 · Seminars in Nephrology
100. Aliskiren Exhibits Similar Pharmacokinetics in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus
     Charlie Weige Zhao, Sujata Vaidyanathan, Ching‐Ming Yeh, Mojdeh Maboudian, H. A. Dieterich · 2006 · Clinical Pharmacokinetics